Celltrion Healthcare Australia

Celltrion Healthcare Australia is the regional subsidiary of Celltrion, a global biopharmaceutical leader specializing in the development and commercialization of biosimilar monoclonal antibodies. The company is responsible for the marketing, sales, and distribution of Celltrion's extensive portfolio in Australia, focusing on high-quality, cost-effective biologic treatments for autoimmune diseases, oncology, and ophthalmology. Key products in their Australian portfolio include Remsima (infliximab), Truxima (rituximab), and Herzuma (trastuzumab). Following the 2023 merger of Celltrion and Celltrion Healthcare, the Australian entity operates as part of a unified global structure aimed at streamlining the supply chain from R&D to patient delivery. The company plays a significant role in the Australian healthcare system by increasing patient access to life-changing biologic therapies through competitive biosimilar alternatives.